Filter Results
:
(1,001)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Managing Growth
But marketing was important. Even if we produced the greatest drugs in the world, we’d be in trouble if we couldn’t get doctors to prescribe them or insurers to pay for them. As for our reluctance to look outside the company for ideas, I like to say that 0.1% of the...
View Details
- 05 Sep 2023
- Book
Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential
In the 1990s, after drugmaker Eli Lilly spent more than a decade and millions of dollars developing the new drug Alimta to treat lung cancer, the medication came up short in effectively treating cancer in expanded trials. While the...
View Details
Keywords:
by Michael Blanding
- January 2007 (Revised August 2008)
- Case
NatuRi Corporation
By: Robert F. Higgins and Virginia Fuller
NatuRi Corporation was a start up, founded in 2005, aiming to manufacture a cholesterol-lowering drug made from the byproducts of rice bran oil production. With operations split between Chennai, India and Boston, Massachusetts, NatuRi faced several challenges,...
View Details
Keywords:
Business Startups;
Decision Choices and Conditions;
Entrepreneurship;
Venture Capital;
Equity;
Investment Funds;
Growth and Development Strategy;
Chennai;
Boston
Higgins, Robert F., and Virginia Fuller. "NatuRi Corporation." Harvard Business School Case 807-027, January 2007. (Revised August 2008.)
- 22 Apr 2009
- Working Paper Summaries
Where is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
- September–October 2020
- Article
The Past, Present, and (Near) Future of Gene Therapy and Gene Editing
By: Julia Pian, Amitabh Chandra and Ariel Dora Stern
Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused...
View Details
Keywords:
Gene Therapy;
Gene Editing;
Impact;
Health Care and Treatment;
Technological Innovation;
Health Testing and Trials;
Venture Capital;
Change
Pian, Julia, Amitabh Chandra, and Ariel Dora Stern. "The Past, Present, and (Near) Future of Gene Therapy and Gene Editing." NEJM Catalyst Innovations in Care Delivery 1, no. 5 (September–October 2020).
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more...
View Details
Keywords:
Valuation;
Cash Flow;
Financing and Loans;
Business Startups;
Financial Strategy;
Medical Devices and Supplies Industry;
Pharmaceutical Industry;
Health Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- March 2014 (Revised November 2020)
- Case
The Novartis Malaria Initiative
By: Michael Chu, Vincent Marie Dessain and Emilie Billaud
The Novartis Malaria Initiative was designed, as a result of a precedent–setting agreement with the World Health Organization in 2001, to provide a breakthrough treatment for malaria—"at no profit"—for public health systems. What had begun as an exemplary act of...
View Details
Keywords:
Health Care and Treatment;
Product Marketing;
Corporate Social Responsibility and Impact;
Social Enterprise;
Pharmaceutical Industry;
Switzerland;
Africa;
Nigeria
Chu, Michael, Vincent Marie Dessain, and Emilie Billaud. "The Novartis Malaria Initiative." Harvard Business School Case 314-103, March 2014. (Revised November 2020.)
- 2020
- Working Paper
What Can Economics Say About Alzheimer's Disease?
By: Amitabh Chandra, Courtney Coile and Corina Mommaerts
Alzheimer’s Disease (AD) affects one in ten people aged 65 or older and is the most expensive disease in the United States. We describe the central economic questions raised by AD. While there is overlap with the economics of aging, the defining features of the...
View Details
Chandra, Amitabh, Courtney Coile, and Corina Mommaerts. "What Can Economics Say About Alzheimer's Disease?" NBER Working Paper Series, No. 27760, August 2020.
- 2016
- Working Paper
Standardized Color in the Food Industry: The Co-Creation of the Food Coloring Business in the United States, 1870–1940
By: Ai Hisano
This working paper examines how, starting in the 1870s, food manufacturers in the United States began to use standardized color, achieved by synthetic dyes, as part of their marketing strategies. Food manufacturers along with dye makers and regulators co-created the...
View Details
Keywords:
Food;
Supply and Industry;
Manufacturing Industry;
Food and Beverage Industry;
United States
Hisano, Ai. "Standardized Color in the Food Industry: The Co-Creation of the Food Coloring Business in the United States, 1870–1940." Harvard Business School Working Paper, No. 17-037, October 2016.
- 27 Jun 2019
- News
Long-Term Investing, Short-Term Thinking
- 2024
- Article
Effects of a Real-Time Information-Based Intervention on Physician Prescribing Behavior
By: Olivia Zhao and Anna D Sinaiko
High out-of-pocket (OOP) prices for prescription drugs create financial difficulties for patients, and cost-related underuse of medications can adversely patient health. Simultaneously, many physicians report a willingness to address affordability concerns with...
View Details
Keywords:
Price;
Health Care and Treatment;
Communication Technology;
Technology Adoption;
Customer Focus and Relationships;
Health Industry
Zhao, Olivia, and Anna D Sinaiko. "Effects of a Real-Time Information-Based Intervention on Physician Prescribing Behavior." Academy of Management Best Paper Proceedings 2024, no. 1 (2024).
- September 2013 (Revised January 2024)
- Case
PAREXEL International Corp.: Scaling Up
By: Regina E. Herzlinger and Natalie Kindred
Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with...
View Details
Keywords:
Research;
Innovation and Invention;
Business Model;
Transformation;
Globalization;
Information Technology;
Competitive Advantage;
Pharmaceutical Industry
Herzlinger, Regina E., and Natalie Kindred. "PAREXEL International Corp.: Scaling Up." Harvard Business School Case 314-056, September 2013. (Revised January 2024.)
- April 2009 (Revised May 2010)
- Case
Partners In Health: HIV Care in Rwanda
By: Michael E. Porter, Scott S. Lee, Joseph Rhatigan and Jim Yong Kim
In 2005, Partners in Health (PIH) was invited by the Rwandan Ministry of Health to assume responsibility for the management of public health care in two rural districts in Eastern Rwanda and create an HIV treatment program at these sites. PIH successfully implemented a...
View Details
Keywords:
Developing Countries and Economies;
Health Care and Treatment;
Health Testing and Trials;
Medical Specialties;
Service Delivery;
Nonprofit Organizations;
Expansion;
Health Industry;
Rwanda
Porter, Michael E., Scott S. Lee, Joseph Rhatigan, and Jim Yong Kim. "Partners In Health: HIV Care in Rwanda." Harvard Business School Case 709-474, April 2009. (Revised May 2010.)
- September 2007
- Article
Investigative Negotiation
By: Deepak Malhotra and Max H. Bazerman
This article includes a one-page preview that quickly summarizes the key ideas and provides an overview of how the concepts work in practice along with suggestions for further reading. Negotiators often fail to achieve results because they channel too much effort into...
View Details
Keywords:
Knowledge Acquisition;
Knowledge Use and Leverage;
Negotiation Process;
Negotiation Tactics;
Motivation and Incentives;
Perspective;
Pharmaceutical Industry
Malhotra, Deepak, and Max H. Bazerman. "Investigative Negotiation." Harvard Business Review 85, no. 9 (September 2007).
- June 2002 (Revised November 2005)
- Case
Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa
By: Debora L. Spar
In the final years of the 20th century, the world was hit by a plague of epidemic proportions--AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought under control through a...
View Details
Keywords:
Patents;
Health Pandemics;
Corporate Social Responsibility and Impact;
Pharmaceutical Industry;
Africa
Spar, Debora L., and Nick Bartlett. "Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa." Harvard Business School Case 702-049, June 2002. (Revised November 2005.)
- Web
Great American Business Leaders of the 20th Century - Leadership
William H. Danforth Ralston Purina Company, 1894–1932 Justin Dart United Drug Company, 1943–1980 Francis B. Davis Jr. United States Rubber Company, 1929–1942 Arthur V. Davis Alcoa, 1910–1928 Charles S. Davis Borg-Warner Corporation,...
View Details
- Research Summary
Health-care Applications
Active postmarketing drug surveillance. There is substantial interest within the U.S. health community and among health policymakers in developing a surveillance system that scans public health databases in order to proactively detect potential drug safety... View Details
- 2008
- Chapter
Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation
By: Arthur A. Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater...
View Details
Keywords:
Geographic Location;
Governing Rules, Regulations, and Reforms;
Health Testing and Trials;
Demand and Consumers;
Pharmaceutical Industry;
European Union;
Germany;
United States
Daemmrich, Arthur A. "Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation." Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, edited by Jean Paul Gaudillière and Volker Hess, 271–290. Berlin, Germany: Max-Planck-Institut für Wissenschaftsgeschichte, 2008.
- 23 Sep 2008
- First Look
First Look: September 23, 2008
Simmons, and G. Goodwin Publication:Journal of Consumer Research (forthcoming) Abstract Four studies examined the willingness of young, healthy individuals to take drugs intended to enhance their own social, emotional, and cognitive...
View Details
Keywords:
Martha Lagace
- December 2022
- Article
The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Context: To what extent does pharmaceutical revenue growth depend on new medicines versus increasing prices for existing medicines? Moreover, does using list prices, as is commonly done, instead of prices net of confidential rebates offered by manufacturers, which are...
View Details
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies." Journal of Health Politics, Policy and Law 47, no. 6 (December 2022): 629–648.